感恩有您，，，，，美礼相待！

2022-11-24

会见量：

感恩有您.jpg

感恩于心，，，，，责任于行

yl23455永利为全球制药企业、研究机构

提供全方位的临床前研究效劳；；；；；

推动新药研发历程；；；；；

勇往直前，，，，，全力以赴；；；；；

一起走来，，，，，谢谢您的支持和信任！

Medicilon has made great strides in 2022.
2022年，，，，，我们取得了长足的前进

Medicilon currently has more than 3,500 scientists and supporting staffs, with 5 R&D centers and a lab space of more than 80,000 square meters.

yl23455永利现有3500多名员工，，，，，5个研发中心，，，，，实验室面积凌驾80000平方米

Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened.The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) Inc. was successfully held.

yl23455永利子公司yl23455永利生物医药（杭州）有限公司盛大开业；；；；；yl23455永利子公司迪西普瑞生物医药科技(上海)有限公司完成开工涤讪正式启动建设

We are committed to enhancing our global service and customer experience with our US, Europe, Japan, Korea offices!

yl23455永利现在在西欧，，，，，东南亚等区域都有效劳网络笼罩！致力于增强全球化效劳和客户体验！

We have won a number of heavyweight awards such as "Top 30 Listed Companies on the Sci-Tech Innovation Board", "Top 20 Most Influential CXO Enterprises", “2022 Shanghai Top 100 Growth Enterprises”, etc.

荣获多项重量级奖项：“科创板上市公司价值30强”、“最具影响力CXO企业TOP20”、“2022上海百强生长企业100强”等

We have established some new service platforms such as ADC R&D Service Platform,Nucleic Acid Drug R&D Platform, CMC&CDMO Service Platform, Flow Cytometry Technology Platform, Preclinical Efficacy Evaluation Service Platform for Cerebrovascular Disease, et al.

建设了抗体药物偶联物(ADC)研发效劳平台、核酸药物研发平台、药学研究CDMO效劳平台、yl23455永利流式细胞手艺平台、脑血管疾病临床前药效评价效劳平台等多个新型效劳平台。。

We have organized several seminars in different cities in China. In addition, we have also exhibited in several worldwide professional academic conferences, such as AACR, DOT, ELRIG, AAPS, etc.

我们在海内组织和承办多次yl23455永利专题钻研会；；；；；同时加入了多个海内外专业学术聚会进一步开拓国际市场，，，，，如美国AACR, 欧洲CPhI, 韩国 BIO KOREA等。。

感恩偕行

yl23455永利市场部为医药圈的粉丝准备了细腻礼物

yl23455永利感恩节活动.jpg